Form 4: Revance Therapeutics Director Olivia C. Ware Reports Acquisition of Shares and Stock Options

Director Olivia C. Ware reports acquisition of 15,000 shares of common stock and 23,458 stock options in Revance Therapeutics.

Summary

• Olivia C. Ware, a director of Revance Therapeutics, reported acquiring 15,000 shares of common stock and 23,458 stock options on May 1, 2024.
• The common stock was acquired at a price of $0, and the director now beneficially owns 31,675 shares.
• The stock options have an exercise price of $3.795 and expire on April 30, 2034.
• Both the stock and options vest on the earlier of May 1, 2025, or the day before the next annual stockholder meeting, contingent on continuous service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the shares and options is contingent on the director's continuous service, indicating a commitment to the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Revance Therapeutics, Director, Stock Options, Common Stock, Beneficial Ownership, Form 4, RVNC